Search results for "Serous"

showing 10 items of 46 documents

The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community.

2021

Abstract In the last decade, a growing attention has been focused on identifying effective therapeutic strategies also in the orphan clinical setting of women with platinum-resistant disease. In this context, secondary cytoreductive surgery (SCS) remains a potential approach only in women with platinum sensitive relapse, but experimental data have been published supporting the role of SCS also in patients with platinum-resistant recurrence. In particular, surgery is emerging as a potential option in specific subgroups of women, such as those patients with low-grade serous histology, or low-volume relapse with disease located in the so-called pharmacological sanctuaries. Furthermore, contras…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentContext (language use)Antineoplastic AgentsPlatinum CompoundsDiseaseHyperthermic Intraperitoneal ChemotherapyCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineMedicineAnimalsHumansIn patientPlatinum resistantChemotherapybusiness.industryCytoreduction Surgical Proceduresmedicine.diseaseCombined Modality TherapySurgerySerous fluid030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPlatinum sensitiveFemaleNeoplasm Recurrence LocalbusinessOvarian cancerBiological features Minimally invasive surgery Personalized treatment Platinum resistant Recurrent ovarian cancer Secondary cytoreductive surgerySeminars in cancer biology
researchProduct

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

2016

High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who …

0301 basic medicineOncologyAdultmedicine.medical_specialtyBevacizumabendocrine system diseasesPrognosimedicine.medical_treatmentHigh-grade serous ovarian carcinoma (HGSOC)Gene ExpressionAntineoplastic AgentsKaplan-Meier EstimateBrief Communication03 medical and health sciences0302 clinical medicineOvarian carcinomaInternal medicineObstetrics and GynaecologyMedicineHumansPlatinumAgedAurora Kinase ANeoplasm StagingGynecologyAged 80 and overOvarian NeoplasmsChemotherapyAURKAbusiness.industryObstetrics and GynecologyRetrospective cohort studyMiddle AgedPrognosisImmunohistochemistryfemale genital diseases and pregnancy complicationsCystadenocarcinoma SerousClinical trialSerous fluid030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleAurora Kinase APersonalized medicineTherapybusinessmedicine.drugJournal of Ovarian Research
researchProduct

Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations.

2017

Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineSurgical oncologyCeliac ArteryInternal medicinemedicineHumansYoung adultCystadenocarcinomaSurvival rateLymph nodeAgedRetrospective StudiesOvarian Neoplasmsbusiness.industryLiver NeoplasmsRetrospective cohort studyCytoreduction Surgical ProceduresMiddle Agedmedicine.diseaseovarian cancer hepatoceliac lymph nodes metastasesPrognosisCystadenocarcinoma SerousEndometrial NeoplasmsSurvival Rate030104 developmental biologymedicine.anatomical_structureSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisSurgery; OncologyAdenocarcinomaLymph Node ExcisionSurgeryFemaleLymph NodesbusinessAdenocarcinoma Clear CellFollow-Up StudiesAnnals of surgical oncology
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

2017

Abstract Purpose The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. Patients and methods This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously tre…

0301 basic medicineOncologyDiarrheamedicine.medical_specialtyIndazolesCyclophosphamideMaximum Tolerated DosePlatinum CompoundsCarcinoma Ovarian EpithelialDisease-Free SurvivalPazopanib03 medical and health sciences0302 clinical medicineLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasms Glandular and EpithelialAdverse effectCyclophosphamideFatigueAgedOvarian NeoplasmsSulfonamidesLeukopeniabusiness.industryObstetrics and GynecologyLeukopeniaMiddle Agedmedicine.diseaseSurgeryRegimen030104 developmental biologyPyrimidinesOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisFallopian tube cancerFemalemedicine.symptomNeoplasm GradingNeoplasm Recurrence LocalbusinessOvarian cancerNeoplasms Cystic Mucinous and Serousmedicine.drugGynecologic oncology
researchProduct

SNVSniffer: an integrated caller for germline and somatic single-nucleotide and indel mutations

2016

Various approaches to calling single-nucleotide variants (SNVs) or insertion-or-deletion (indel) mutations have been developed based on next-generation sequencing (NGS). However, most of them are dedicated to a particular type of mutation, e.g. germline SNVs in normal cells, somatic SNVs in cancer/tumor cells, or indels only. In the literature, efficient and integrated callers for both germline and somatic SNVs/indels have not yet been extensively investigated. We present SNVSniffer, an efficient and integrated caller identifying both germline and somatic SNVs/indels from NGS data. In this algorithm, we propose the use of Bayesian probabilistic models to identify SNVs and investigate a mult…

0301 basic medicineSomatic cellBayesian probabilityBiologyPolymorphism Single NucleotideGermline03 medical and health sciencesGene FrequencyINDEL MutationStructural BiologyModelling and SimulationIndel callingGenetic variationHumansAlleleIndelMolecular BiologyOvarian NeoplasmsGeneticsResearchApplied MathematicsComputational BiologyHigh-Throughput Nucleotide SequencingSNP callingSomatic SNV callingCystadenocarcinoma SerousComputer Science ApplicationsGerm Cells030104 developmental biologyBayesian modelModeling and SimulationMutation (genetic algorithm)FemaleMultinomial distributionAlgorithmsBMC Systems Biology
researchProduct

Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines

1992

Six permanent human tumor cell lines (OV-MZ-1 to 6) were established from 6 patients with serous adenocarcinomas of the ovary. These cell lines were derived from both solid tumors and ascites, from pre-treated and untreated patients, and are available over a range of in vitro passage numbers. The tumor cells grow its monolayers and develop foci of “piled-up” cells in confluent cultures. Flow cytophotometry showed that all the lines exhibited DNA hyperdiploidy with DNA tetraploidy in one cell line and DNA aneuploidy in the other cell lines. The mean population doubling time ranged from 24 to 52 hr. Transmission electron microscopy demonstrated that the tumor cells of all cell lines exhibited…

AdultCancer ResearchPathologymedicine.medical_specialtyTransplantation HeterologousVimentinOvaryMiceCytokeratinIntermediate Filament ProteinsOvarian carcinomaTumor Cells CulturedmedicineAnimalsHumansAntigens Tumor-Associated CarbohydrateAgedOvarian NeoplasmsbiologyCarcinomaDNA NeoplasmMiddle Agedmedicine.diseaseImmunohistochemistryMolecular biologyCarcinoembryonic AntigenSerous fluidmedicine.anatomical_structureOncologyCell culturebiology.proteinAdenocarcinomaFemaleNeoplasm TransplantationIntracellularInternational Journal of Cancer
researchProduct

Laparoscopic surgery for isolated inguinal node relapse of high grade serous ovarian cancer using a bipolar combination instrument

2020

Abstract Objective To demonstrate step-by-step minimally invasive surgical technique for dissection of isolated inguinal node relapse of high grade serous ovarian cancer. Methods A 54-year-old woman, BRCA1 +, underwent to open abdominal total hysterectomy, bilateral salpingo-oophorectomy, total omentectomy, pelvic and aortic lymphadenectomy with zero residual disease, for high grade serous ovarian carcinoma FIGO stage IIB. After surgery, patient underwent platinum-based chemotherapy for six cycles and follow-up examinations every 3 months for the first year and biannual for the second one. Abdominal TC-PET scan after 18 months revealed a right distal iliac external/inguinal nodal relapse (S…

AdultLaparoscopic surgerymedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInguinal CanalOvarian carcinomamedicineHumansMinimally Invasive Surgical ProceduresLaparoscopyOvarian NeoplasmsHysterectomymedicine.diagnostic_testbusiness.industryPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsCystadenocarcinoma SerousSurgerySerous fluidDeep inguinal ringmedicine.anatomical_structureOncologyCancer Inguinal Laparoscopy Ovarian Relapse SurgeryFemaleLaparoscopySurgeryLymphadenectomyNeoplasm Recurrence LocalOvarian cancerbusinessSurgical Oncology
researchProduct

Parotid sialosis: morphometrical analysis of the glandular parenchyme and stroma among diabetic and alcoholic patients

2009

J Oral Pathol Med (2010) 39: 10–15 Background:  Among the agents that cause parotid sialosis, diabetes mellitus type 2 and chronic alcoholism are included. In this study, the morphometrical modifications in the diabetic parotid sialosis were determined to compare them with the histopathological characteristics of alcoholic parotid sialosis. Methods:  Five parotid biopsy samples obtained from patients with diabetic sialosis, 12 samples from patients with alcoholic sialosis and seven from individuals without these pathologies (control group) were analyzed. A morphometrical study of parotid parenchyme and stroma, using a digital image analyzer attached to an optical microscope, was carried out…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyBiopsyAdipose tissueCell CountEpitheliumPathology and Forensic MedicineMuscle hypertrophystomatognathic systemLiver Cirrhosis AlcoholicDiabetes mellitusParenchymaBiopsyImage Processing Computer-AssistedmedicineHumansSalivary DuctsAgedAged 80 and overMicroscopymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseSialadenitisParotid glandAlcoholismSerous fluidmedicine.anatomical_structureAdipose TissueDiabetes Mellitus Type 2OtorhinolaryngologyPeriodonticsFemaleParotid DiseasesOral SurgerybusinessJournal of Oral Pathology & Medicine
researchProduct

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

2010

Abstract Background The aim of this population-based study was to assess independent prognostic factors in ovarian cancer using relative survival (RS) and to investigate changes in RS rates from 1982 to 2005. Methods Data on 748 patients with ovarian cancer were provided by the Côte d'Or gynaecologic cancer registry. The RS was estimated using a generalized linear model with a Poisson error structure. Relative survival and its 95% confidence interval (CI) were described at the following specific time points 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with multivariate analyses of RS. Results The median follow-up was 12 years. The RS rates at 1, 3 and 5 years …

AdultOncologymedicine.medical_specialtyCancer ResearchMultivariate analysisAdolescentPopulationMedical Oncologylcsh:RC254-282Internal medicinemedicineGeneticsHumansRegistriesChildeducationSurvival rateAgedAged 80 and overOvarian NeoplasmsGynecologyeducation.field_of_studyRelative survivalbusiness.industryCancerMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseConfidence intervalSurvival RateSerous fluidTreatment OutcomeOncologyFemaleFranceOvarian cancerbusinessResearch ArticleBMC Cancer
researchProduct